RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors

Laboratory Investigation

Volumn 85, Issue 9, 2005, Pages 1065-1075

  Nakamura, Nobuki ^a   Carney, J Aidan ^a   Jin, Long ^a   Kajita, Sabine ^a   Pallares, Judit ^a   Zhang, Heyu ^a   Qian, Xiang ^a   Sebo, Thomas J ^a   Erickson, Lori A ^a   Lloyd, Ricardo V ^a  

^a MAYO CLINIC   (United States)

Author keywords

BRAF; NORE1A; Papillary carcinoma; RASSF1A; Thyroid

Indexed keywords

B RAF KINASE; NOREA1A GENE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; PRIMER DNA; RASSF1 PROTEIN, HUMAN; RASSF5 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; DNA SEQUENCE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYALINE DEGENERATION; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; METHYLATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID TUMOR; TUMOR CELL LINE; TUMOR GROWTH; WESTERN BLOTTING; DNA METHYLATION; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION;

BLOTTING, WESTERN; CELL LINE, TUMOR; DNA METHYLATION; DNA PRIMERS; HUMANS; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MONOMERIC GTP-BINDING PROTEINS; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 27744469417     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700306     Document Type: Article

References (61)

1. Soares P, Maximo V, Sobrinho-Simoes M. Molecular pathology of papillary, follicular and Hurthle cell carcinomas of the thyroid. Arkh Patol 2003;65:45-47.
2. Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg Oncol 2003;12:69-90.
3. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-319.
4. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-699.
5. Dreijerink K, Braga E, Kuzmin I, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 2001;98:7504-7509.
6. Kuzmin I, Gillespie JW, Protopopov A, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002;62:3498-3502.
7. Shivakumar L, Minna J, Sakamaki T, et al. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 2002;22:4309-4318.
8. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-3109.
9. Dammann R, Takahashi T, Pfeifer GP. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 2001;20:3563-3567.
10. Yoon JH, Dammann R, Pfeifer GP. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 2001;94:212-217.
11. van Engeland M, Roemen GM, Brink M, et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 2002;21:3792-3795.
12. Hasegawa M, Nelson HH, Peters E, et al. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002;21:4231-4236.
13. Toyooka S, Carbone M, Toyooka KO, et al. Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene 2002;21:4340-4344.
14. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002;21:4345-4349.
15. Schagdarsurengin U, Gimm O, Hoang-Vu C, et al. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 2002;62:3698-3701.
16. Wong IH, Chan J, Wong J, et al. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res 2004;10:994-1002.
17. Xing M, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 2004;64:1664-1668.
18. Vavvas D, Li X, Avruch J, et al. Identification of Nore1 as a potential Ras effector. J Biol Chem 1998;273: 5439-5442.
19. Tommasi S, Dammann R, Jin SG, et al. RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 2002;21:2713-2720.
20. Hesson L, Dallol A, Minna JD, et al. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 2003;22: 947-954.
21. Bonner TI, Kerby SB, Sutrave P, et al. Structure and biological activity of human homologs of the raf/mil oncogene. Mol Cell Biol 1985;5:1400-1407.
22. Bonner TI, Oppermann H, Seeburg P, et al. The complete coding sequence of the human raf oncogene and the corresponding structure of the c-raf-1 gene. Nucleic Acids Res 1986;14:1009-1015.
23. Huebner K, ar-Rushdi A, Griffin CA, et al. Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human. Proc Natl Acad Sci USA 1986;83:3934-3938.
24. Huleihel M, Goldsborough M, Cleveland J, et al. Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol Cell Biol 1986;6: 2655-2662.
25. Beck TW, Huleihel M, Gunnell M, et al. The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. Nucleic Acids Res 1987;15:595-609.
26. Ikawa S, Fukui M, Ueyama Y, et al. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol 1988;8:2651-2654.
27. Sithanandam G, Kolch W, Duh FM, et al. Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene 1990;5:1775-1780.
28. Eychene A, Barnier JV, Apiou F, et al. Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B-raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene. Oncogene 1992;7:1657-1660.
29. Stephens RM, Sithanandam G, Copeland TD, et al. 95-kilodalton B-Raf serine/threonine kinase: identification of the protein and its major autophosphorylation site. Mol Cell Biol 1992;12:3733-3742.
30. Hillier LW, Fulton RS, Fulton LA, et al. The DNA sequence of human chromosome 7. Nature 2003;424: 157-164.
31. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001;93: 53-62.
32. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954.
33. Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003;9:3362-3368.
34. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
35. Domingo E, Espin E, Armengol M, et al. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 2004;39:138-142.
36. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457.
37. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-4397.
38. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63: 4561-4567.
39. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992;89:1827-1831.
40. Irimia M, Fraga MF, Sanchez-Cespedes M, et al. CpG island promoter hypermethylation of the Ras-effector gene RASSF1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene 2004;23: 8695-8699.
41. Hesson L, Bieche I, Krex D, et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 2004;23:2408-2419.
42. Lae ME, Roche PC, Jin L, et al. Desmoplastic small round cell tumor: a clinicopathologic, immunohistochemical, and molecular study of 32 tumors. Am J Surg Pathol 2002;26:823-835.
43. Ruebel KH, Jin L, Zhang S, et al. Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas. Endocr Pathol 2001;12:281-289.
44. Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003;63: 2251-2255.
45. Lloyd RV, Ruebel KH, Zhang S, et al. Pituitary hyperplasia in glycoprotein hormone alpha subunit-, p18(INK4C)-, and p27(kip-1)-null mice: analysis of proteins influencing p27(kip-1) ubiquitin degradation. Am J Pathol 2002;160:1171-1179.
46. Chow LS, Lo KW, Kwong J, et al. Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma. Oncol Rep 2004;12:781-787.
47. Mehrotra J, Vali M, McVeigh M, et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain and lung. Clin Cancer Res 2004;10:3104-3109.
48. Cohen Y, King M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95:625-627.
49. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003;22: 4578-4580.
50. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22:6455-6457.
51. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-5404.
52. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004;202: 247-251.
53. Xing M, Vasko V, Tallini G, et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 2004;89:1365-1368.
54. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 2004;444:572-576.
55. Cohen Y, Rosenbaum E, Clark DP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004;10:2761-2765.
56. Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004;89:2414-2420.
57. Nikiforova MN, Ciampi R, Salvatore G, et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 2004;209:1-6.
58. Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004;89: 2867-2872.
59. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004;61:239-243.
60. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004;23: 7436-7440.
61. Begum S, Rosenbaum E, Henrique R, et al. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 2004;17:1359-1363.